Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.
| Revenue (TTM) | $915.25M |
| Gross Profit (TTM) | $785.06M |
| EBITDA | $67.34M |
| Operating Margin | -0.55% |
| Return on Equity | 18.40% |
| Return on Assets | 3.91% |
| Revenue/Share (TTM) | $31.43 |
| Book Value | $27.51 |
| Price-to-Book | 1.71 |
| Price-to-Sales (TTM) | 1.58 |
| EV/Revenue | 1.2 |
| EV/EBITDA | 13.36 |
| Quarterly Earnings Growth (YoY) | 308.40% |
| Quarterly Revenue Growth (YoY) | 1.60% |
| Shares Outstanding | $28.81M |
| Float | $25.47M |
| % Insiders | 1.14% |
| % Institutions | 123.02% |
Volatility is currently expanding
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed.
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2026 after the close of trading on Monday, August 3. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inspire Medical Systems, Inc. (NYSE: INSP). In August of 2025, contrary to the Company's repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elonga.
Inspire Medical Systems, Inc. (INSP) Presents at Wells Fargo 2026 MedTech Innovation Spotlight Transcript
Inspire Medical's SLEEP 2026 updates spotlight new Inspire V data, remote patient tools and research supporting wider OSA therapy adoption.
Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
INSP beats Q1 estimates but slashes 2026 outlook as reimbursement disruptions and WISeR program weigh on growth and procedure volumes.
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2026.
MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, 2026. Inspire is scheduled to present at 11:00 a.m.
